| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3284349 | Clinical Gastroenterology and Hepatology | 2009 | 8 Pages |
Abstract
Pretreatment YKL-40 levels are an independent predictor of initial virologic response to peginterferon and ribavirin treatment. Levels of all 4 serum fibrosis markers decreased significantly in the SVR patients, consistent with reduced hepatic fibrogenesis. Measuring serum fibrosis marker levels before and after antiviral therapy may provide important prognostic information in CHC patients.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Robert J. Fontana, Herbert L. Bonkovsky, Deepa Naishadham, Jules L. Dienstag, Richard K. Sterling, Anna S.F. Lok, Grace L. Su, The Halt-C Trial Group The Halt-C Trial Group,